BioCentury
ARTICLE | Company News

FDA approves Paratek antibiotics

October 2, 2018 11:45 PM UTC

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) received a pair of FDA approvals Tuesday for Nuzyra omadacycline and Seysara sarecycline. The agency approved Nuzyra to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). Seysara was approved in inflammatory lesions of non-nodular moderate to severe acne vulgaris.

Paratek said Nuzyra, an aminomethylcycline antibiotic that is designed to overcome tetracycline resistance, is the first once-daily IV and oral antibiotic approved to treat both indications in almost 20 years. Its label includes language noting an imbalance of mortality compared with moxifloxacin...

BCIQ Company Profiles

Paratek Pharmaceuticals Inc.